Cell proliferation inhibitor
US8710022B2 · kind B2 · utility
14Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 17, 2009 |
| Grant date | Apr 29, 2014 |
| Priority date | — |
| Expiry date | Sep 30, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present inventors revealed a TTF-1-specific oncogenic process by elucidating the molecular mechanism regulated by the master regulatory factor TTF-1. The present inventors focused on the elucidation of the essence of the lineage-specific survival signal which is a novel canceration signal. Thus, the present inventors found that the expression of ROR1, which is a receptor tyrosine kinase, is induced by the master regulatory factor TTF-1, and demonstrated the presence of a characteristic canceration signal transduction system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.